磷脂酰肌醇蛋白聚糖3(GPC3)等多因子檢測試劑盒(流式熒光發光法)
Multiplex Assay Kit for Glypican 3 (GPC3) ,etc. by FLIA (Flow Luminescence Immunoassay)
DGSX; OCI5; SDYS; SGB; SGBS1; MXR7; Glypican Proteoglycan 3; GTR2-2; Intestinal protein OCI-5; Secreted glypican-3
（注：單次混測多因子不超過8個指標 ）
- 編號LMA971Ra
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱，不同的物種。
- 實驗方法雙抗夾心
- 反應時長3.5h
- 檢測范圍0.01-10ng/mL
- 靈敏度最小可檢測劑量小于等于0.003 ng/mL.
- 樣本類型serum, plasma, tissue homogenates and other biological fluids
- 下載 英文說明書 中文說明書
- 規格 8指標數 7指標數 6指標數 5指標數 4指標數 3指標數 2指標數1指標數
- 價格 ¥ 2562 ¥ 2660 ¥ 2808 ¥ 3005 ¥ 3202 ¥ 3497 ¥ 3941 ¥ 4926 添加到價格計算器 計算器
- 欲了解實際交易價格和更多情況，請與當地經銷商聯系!
-
產品包裝(模擬)
-
產品包裝(模擬)
-
通過ISO 9001、ISO 13485質量體系認證
特異性
本試劑盒用于檢測磷脂酰肌醇蛋白聚糖3(GPC3)等多因子檢測試劑盒(流式熒光發光法)，經檢測與其它相似物質無明顯交叉反應。
由于受到技術及樣本來源的限制，不可能完成對所有相關或相似物質交叉反應檢測，因此本試劑盒有可能與未經檢測的其它物質有交叉反應。
回收率
分別于定值血清及血漿樣本中加入一定量的磷脂酰肌醇蛋白聚糖3(GPC3)等多因子檢測試劑盒(流式熒光發光法)（加標樣品），重復測定并計算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 86-101 | 91 |
| EDTA plasma(n=5) | 95-102 | 98 |
| heparin plasma(n=5) | 92-99 | 96 |
| sodium citrate plasma(n=5) | 79-93 | 82 |
精密度
精密度用樣品測定值的變異系數CV表示。CV(%) = SD/mean×100
批內差：取同批次試劑盒對低、中、高值定值樣本進行定量檢測,每份樣本連續測定20 次，分別計算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進行定量測定，每個樣本使用同一試劑盒重復測定8次，分別計算不同濃度樣本的平均值及SD值。
批內差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內加入適量的磷脂酰肌醇蛋白聚糖3(GPC3)等多因子檢測試劑盒(流式熒光發光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中磷脂酰肌醇蛋白聚糖3(GPC3)等多因子檢測試劑盒(流式熒光發光法)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 98-105% | 96-105% | 78-101% | 94-101% |
| EDTA plasma(n=5) | 94-105% | 83-103% | 87-99% | 85-104% |
| heparin plasma(n=5) | 93-102% | 90-105% | 89-96% | 85-104% |
| sodium citrate plasma(n=5) | 84-93% | 82-89% | 83-97% | 78-92% |
穩定性
經測定，試劑盒在有效期內按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實驗室的環境條件需盡量保持一致，尤其是實驗室內溫度、濕度及溫育條件。其次由同一實驗員來進行操作可減少人為誤差。
實驗流程
1. 實驗前標準品、試劑及樣本準備；
2. 加樣（標準品、樣本、磁珠）標準品或樣本100μL及磁珠10μL，
37°C酶標板振蕩器孵育90分鐘；
3. 磁吸甩干，加檢測溶液A100μL，37°C酶標板振蕩器孵育60分鐘；
4. 磁吸洗板3次；
5. 加檢測溶液B100μL，37°C振動孵育30分鐘；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋渦震蕩2分鐘后讀數。
實驗原理
將磷脂酰肌醇蛋白聚糖3(GPC3)等多因子檢測試劑盒(流式熒光發光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標準品或標本以及磁珠，其中的磷脂酰肌醇蛋白聚糖3(GPC3)等多因子檢測試劑盒(流式熒光發光法)與連接于固相載體上的抗體結合，然后加入生物素化的磷脂酰肌醇蛋白聚糖3(GPC3)等多因子檢測試劑盒(流式熒光發光法)抗體，將未結合的生物素化抗體洗凈后，加入PE標記的親和素，再次徹底洗滌后即可上機讀數。MFI值和樣品中的磷脂酰肌醇蛋白聚糖3(GPC3)等多因子檢測試劑盒(流式熒光發光法)呈正相關。
贈品
增值服務
相關產品
| 編號 | 適用物種：Rattus norvegicus (Rat，大鼠) | 應用(僅供研究使用，不用于臨床診斷！) |
| RPA971Ra01 | 磷脂酰肌醇蛋白聚糖3(GPC3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA971Ra01 | 磷脂酰肌醇蛋白聚糖3(GPC3)多克隆抗體 | WB; IHC; ICC; IP. |
| MAA971Ra21 | 磷脂酰肌醇蛋白聚糖3(GPC3)單克隆抗體 | WB; IHC; ICC; IP. |
| SEA971Ra | 磷脂酰肌醇蛋白聚糖3(GPC3)檢測試劑盒(酶聯免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA971Ra | 磷脂酰肌醇蛋白聚糖3(GPC3)等多因子檢測試劑盒(流式熒光發光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| Nature and Science | Diagnostic Role of Serum Glypican-3 as a Tumor Marker for Hepatocellular Carcinoma [Sciencepub:10043238] |
| Journal of Applied Pharmaceutical Science | Cytotoxic effects of antiglypican-3 against HepG2 cell line [Ebscohost: Source] |
| Asian Pacific Journal of Cancer Prevention | Can Glypican3 be Diagnostic for Early Hepatocellular Carcinoma among Egyptian Patients? [Pubmed: 24460300] |
| Clin Biochem. | Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: A systematic review and meta-analysis [Pubmed: 24362268] |
| Science and Nature | Diagnostic Role of Serum Glypican-3 as Hepatocellular Carcinoma [Zolcat: Source] |
| Alexandria Journal of Medicine | Role of serum glypican-3 in the diagnosis and differentiation of small hepatocellular carcinoma from hepatitis-C virus cirrhosis [ScienceDirect: S2090506814000062] |
| J Egypt Natl Canc Inst. | Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients. [Pubmed:24841158] |
| European Journal of Pharmacology | Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma [Pubmed:25449037] |
| Hepatobiliary Pancreat Dis Int | Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern [abstract:abstract4525.shtml] |
| Clinical?and Molecular Hepatology? | Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis [pmc:articles] |
| Wiley | Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment [pubmed:28621802] |
| Biomedicine & Pharmacotherapy | Cytotoxic and partial hepatoprotective activity of sodium ascorbate against hepatocellular carcinoma through inhibition of sulfatase-2 and [Pubmed:29669302] |
| Journal of Cancer and Clinical Oncology | Development and Validation of a Two-Site Immunoradiometric assay for Glypican-3 in plasma: Implication in Diagnosis of Hepatocellular Carcinoma [Researchgate:Source] |
| Turkish?journal?of?oncology | Serum Glypican-3, Vascular Endothelial Growth Factor, and Interleukin-6 Levels in Hepatocellular Carcinoma [10.5505:tjo.2018.1742] |
| Intensive?Care?Medicine?Experimental | Elevated plasma glypicans are associated with organ failure in patients with infection [Pubmed: 30618011] |
| VALUE OF SERUM GLYPICAN 3 AS A PREDICTIVE TOOL FOR EARLY DIAGNOSIS OF HEPATOCELLULAR CARCINOMA (HCC) [] | |
| ADVANCED RESEARCHES | Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C [] |
| Life Sci | Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and?… [Pubmed:35640776] |
